LT3288379T - Peptidų kompozicijos ir naudojimo būdai - Google Patents
Peptidų kompozicijos ir naudojimo būdaiInfo
- Publication number
- LT3288379T LT3288379T LTEPPCT/US2016/030098T LT16030098T LT3288379T LT 3288379 T LT3288379 T LT 3288379T LT 16030098 T LT16030098 T LT 16030098T LT 3288379 T LT3288379 T LT 3288379T
- Authority
- LT
- Lithuania
- Prior art keywords
- peptides
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155711P | 2015-05-01 | 2015-05-01 | |
| PCT/US2016/030098 WO2016178993A1 (en) | 2015-05-01 | 2016-04-29 | Peptide compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3288379T true LT3288379T (lt) | 2022-02-25 |
Family
ID=57217771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2016/030098T LT3288379T (lt) | 2015-05-01 | 2016-04-29 | Peptidų kompozicijos ir naudojimo būdai |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10508134B2 (https=) |
| EP (3) | EP3997981A1 (https=) |
| JP (2) | JP6884755B2 (https=) |
| KR (2) | KR20240046280A (https=) |
| CN (2) | CN113651873B (https=) |
| AU (1) | AU2016258837B2 (https=) |
| CA (1) | CA2984154A1 (https=) |
| CY (1) | CY1124911T1 (https=) |
| DK (1) | DK3288379T3 (https=) |
| EA (2) | EA202090184A3 (https=) |
| ES (1) | ES2906173T3 (https=) |
| HR (1) | HRP20220138T1 (https=) |
| HU (1) | HUE057883T2 (https=) |
| LT (1) | LT3288379T (https=) |
| MX (1) | MX387317B (https=) |
| PL (1) | PL3288379T3 (https=) |
| PT (1) | PT3288379T (https=) |
| RS (1) | RS62866B1 (https=) |
| SI (1) | SI3288379T1 (https=) |
| SM (1) | SMT202200069T1 (https=) |
| WO (1) | WO2016178993A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3288379T (lt) | 2015-05-01 | 2022-02-25 | Onl Therapeutics, Inc. | Peptidų kompozicijos ir naudojimo būdai |
| WO2019183246A1 (en) * | 2018-03-20 | 2019-09-26 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| EP3810082A1 (en) * | 2018-06-19 | 2021-04-28 | Cella Therapeutics, LLC | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| WO2021127052A1 (en) * | 2019-12-18 | 2021-06-24 | Cella Therapeutics, Llc | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR |
| EP4355349A4 (en) * | 2021-06-15 | 2025-04-16 | ONL Therapeutics, Inc. | Methods and compositions for treating eye diseases and disorders |
| AU2022311780A1 (en) * | 2021-07-13 | 2024-02-08 | Onl Therapeutics, Inc. | Methods and compositions for improving visual function in ocular diseases and disorders |
| WO2023129766A1 (en) * | 2021-12-27 | 2023-07-06 | Onl Therapeutics, Inc. | Sfasl for inhibiting rpe cell death and associated disorders |
| EP4565596A1 (en) * | 2022-08-05 | 2025-06-11 | ONL Therapeutics, Inc. | Peptide compositions and methods of use |
| US20260062449A1 (en) * | 2022-08-05 | 2026-03-05 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| EP4698204A1 (en) * | 2023-04-19 | 2026-02-25 | ONL Therapeutics, Inc. | Methods and compositions for treating rnfl thinning |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5532123A (en) * | 1990-07-11 | 1996-07-02 | New York University | Receptor-type phosphotyrosine phosphatase-γ |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| JP3187201B2 (ja) * | 1992-05-14 | 2001-07-11 | 三共株式会社 | Ｃ末端にプロリンアミドを有するペプチドの製法 |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| JP3460863B2 (ja) | 1993-09-17 | 2003-10-27 | 三菱電機株式会社 | 半導体装置の製造方法 |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6001962A (en) * | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
| US6363020B1 (en) | 1999-12-06 | 2002-03-26 | Virage Logic Corp. | Architecture with multi-instance redundancy implementation |
| US6480428B2 (en) | 2000-12-19 | 2002-11-12 | Winbond Electronics Corporation | Redundant circuit for memory device |
| US7459527B2 (en) * | 2004-03-31 | 2008-12-02 | Xencor, Inc. | BMP-7 variants with improved properties |
| CA2563691A1 (en) | 2004-04-23 | 2005-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Cell death modulation via antagonists of fasl and fas activation |
| CA2607608A1 (en) * | 2005-05-10 | 2006-11-16 | Alcon, Inc. | Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders |
| WO2007056457A2 (en) * | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| JP2009518308A (ja) * | 2005-12-01 | 2009-05-07 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | アポトーシスを阻害するための化合物及び方法 |
| EP2222696A1 (en) * | 2007-12-21 | 2010-09-01 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
| CN102449140B (zh) * | 2009-03-03 | 2014-11-26 | 密执安大学评议会 | 抑制光感受器凋亡的方法 |
| CN102365093A (zh) * | 2009-03-30 | 2012-02-29 | 参天制药株式会社 | 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途 |
| WO2011017350A2 (en) * | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| WO2012170392A2 (en) * | 2011-06-06 | 2012-12-13 | Kineta One, Llc | Shk-based pharmaceutical compositions and methods of manufacturing and using the same |
| WO2013106909A1 (en) | 2012-01-18 | 2013-07-25 | Governing Council Of The University Of Toronto | Novel peptides and methods and uses thereof for preventing retinal disorders |
| WO2013191352A1 (en) * | 2012-06-21 | 2013-12-27 | Hanall Biopharma Co., Ltd. | New uses of modified human tumor necrosis factor receptor-1 polypeptide |
| US20150265679A1 (en) * | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| JP2018510359A (ja) | 2015-02-05 | 2018-04-12 | イミューンアレイ ユーエスエイ インコーポレイテッド | 脳損傷または神経変性を診断するための方法および組成物 |
| US20190201500A1 (en) | 2015-05-01 | 2019-07-04 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| LT3288379T (lt) | 2015-05-01 | 2022-02-25 | Onl Therapeutics, Inc. | Peptidų kompozicijos ir naudojimo būdai |
| CN110177577A (zh) | 2016-07-05 | 2019-08-27 | 马萨诸塞大学 | Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| WO2019183246A1 (en) | 2018-03-20 | 2019-09-26 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| EP3810082A1 (en) | 2018-06-19 | 2021-04-28 | Cella Therapeutics, LLC | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
-
2016
- 2016-04-29 LT LTEPPCT/US2016/030098T patent/LT3288379T/lt unknown
- 2016-04-29 SI SI201631458T patent/SI3288379T1/sl unknown
- 2016-04-29 AU AU2016258837A patent/AU2016258837B2/en active Active
- 2016-04-29 KR KR1020247010090A patent/KR20240046280A/ko not_active Ceased
- 2016-04-29 JP JP2018508624A patent/JP6884755B2/ja active Active
- 2016-04-29 CN CN202110665678.1A patent/CN113651873B/zh active Active
- 2016-04-29 MX MX2017014075A patent/MX387317B/es unknown
- 2016-04-29 SM SM20220069T patent/SMT202200069T1/it unknown
- 2016-04-29 RS RS20220095A patent/RS62866B1/sr unknown
- 2016-04-29 ES ES16789830T patent/ES2906173T3/es active Active
- 2016-04-29 DK DK16789830.3T patent/DK3288379T3/da active
- 2016-04-29 HU HUE16789830A patent/HUE057883T2/hu unknown
- 2016-04-29 KR KR1020177034366A patent/KR102652804B1/ko active Active
- 2016-04-29 EP EP21200594.6A patent/EP3997981A1/en not_active Withdrawn
- 2016-04-29 WO PCT/US2016/030098 patent/WO2016178993A1/en not_active Ceased
- 2016-04-29 CN CN201680038258.8A patent/CN107708416B/zh active Active
- 2016-04-29 CA CA2984154A patent/CA2984154A1/en active Pending
- 2016-04-29 EP EP16789830.3A patent/EP3288379B1/en active Active
- 2016-04-29 US US15/570,948 patent/US10508134B2/en active Active
- 2016-04-29 PT PT167898303T patent/PT3288379T/pt unknown
- 2016-04-29 EA EA202090184A patent/EA202090184A3/ru unknown
- 2016-04-29 EA EA201792399A patent/EA035293B1/ru unknown
- 2016-04-29 HR HRP20220138TT patent/HRP20220138T1/hr unknown
- 2016-04-29 PL PL16789830T patent/PL3288379T3/pl unknown
- 2016-04-29 EP EP25186051.6A patent/EP4623925A3/en active Pending
-
2019
- 2019-11-04 US US16/673,513 patent/US10829518B2/en active Active
-
2020
- 2020-10-06 US US17/064,495 patent/US11597749B2/en active Active
-
2021
- 2021-05-12 JP JP2021080927A patent/JP2021120400A/ja active Pending
-
2022
- 2022-02-02 CY CY20221100088T patent/CY1124911T1/el unknown
-
2023
- 2023-01-24 US US18/159,021 patent/US12258425B2/en active Active
-
2025
- 2025-02-14 US US19/054,490 patent/US20250346631A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285286A (en) | Transposase polypeptides and uses thereof | |
| LT3370770T (lt) | Anti-cd38 antikūnų poodinės kompozicijos ir jų panaudojimas | |
| LT3443009T (lt) | Anti-tim-3 antikūnai ir kompozicijos | |
| LT3607069T (lt) | Produktai ir kompozicijos | |
| IL284236A (en) | Modifications and uses of conotoxin peptides | |
| LT3317284T (lt) | Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai | |
| LT3426285T (lt) | Pegilintos urikazės kompozicijos ir dozės | |
| LT3283107T (lt) | Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją | |
| LT3280441T (lt) | Anti-sortilino antikūnai ir jų naudojimo būdai | |
| LT3394259T (lt) | Tau raiškos mažinimo kompozicijos ir metodai | |
| LT3102555T (lt) | Junginių kompozicijos ir jų panaudojimas | |
| IL247292A0 (en) | Antireflective coating compositions and processes thereof | |
| LT3288379T (lt) | Peptidų kompozicijos ir naudojimo būdai | |
| PL3498292T3 (pl) | Konstrukty białka uspa2 i ich zastosowania | |
| DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| LT3265126T (lt) | Tesofensino ir metoprololio derinio kompozicija | |
| IL248223A0 (en) | Vaccine compositions | |
| LT3110837T (lt) | Tatk-cdkl5 sulieti baltymai, kompozicijos, sudėtys ir jų panaudojimas | |
| EP3310373A4 (en) | Thiol-ene based peptide stapling and uses thereof | |
| LT3324938T (lt) | Vietinio veikimo kompozicijos ir gydymo būdai | |
| DK3099314T3 (da) | Tolerogene sammensætninger og anvendelser deraf | |
| EP3473373A4 (en) | solder compositions | |
| EP3334750A4 (en) | Peptidic tgf-beta antagonists | |
| EP3388089A4 (en) | PEPTIDE COMPOSITION |